Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy the following criteria at study entry:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse.~* Written informed consent obtained from the subject.~* Free of an acute aggravation of the health status as established by medical history and clinical examination before entering into the study.~Elderly adults:~• A man or woman 65 year of age or older at the time of the first vaccination.~Young adults:~* Man or woman between the ages of 18 and 40 years, inclusive.~* If the subject is female, she must be of non-childbearing potential or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.~* Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to Visit 4 after vaccination and of an influenza vaccine other than the study vaccines up to Visit 4.~* Vaccination against influenza since February 2008 with a seasonal influenza vaccine.~* Previous vaccination in the last three years with an investigational adjuvanted vaccine candidate seasonal or pandemic influenza vaccine.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of hypersensivity to a previous dose of influenza vaccine.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg or chicken protein.~* Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation or pre-existing laboratory screening tests.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.~* Any medical conditions in which intramuscular injections are contraindicated.~* Pregnant or lactating female.~* Female of childbearing age planning to become pregnant or planning to discontinue contraceptive precautions.~* Any medical condition that in the opinion of the investigator precludes the collection of blood volumes as required by the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- New generation influenza vaccine GSK2186877A Group (Type: EXPERIMENTAL): Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
- Fluarix elderly Group (Type: ACTIVE_COMPARATOR): Subjects aged \>= 65 years receiving 1 dose of Fluarix vaccine at Day 0
- Fluarix young Group (Type: ACTIVE_COMPARATOR): Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).